{"id":4733,"date":"2019-04-11T16:33:31","date_gmt":"2019-04-11T11:03:31","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=4733"},"modified":"2023-06-14T11:49:02","modified_gmt":"2023-06-14T06:19:02","slug":"the-business-cocktail-60","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-60","title":{"rendered":"Inozyme Raises $67M; Shanghai Miracogen partners with Synaffix; EdiGENE raises $15M; Antengene announces its expansion"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-69fea8ef05fd4\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-69fea8ef05fd4\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-60\/#Inozyme_Pharma_Raises_USD_67_Million_in_Series_A2_Financing\" >Inozyme Pharma Raises USD 67 Million in Series A2 Financing<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-60\/#Shanghai_Miracogen_partners_with_Synaffix_to_accelerate_its_pipeline\" >Shanghai Miracogen partners with Synaffix to accelerate its pipeline<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-60\/#EdiGENE_raises_USD_15M_to_progress_its_pipeline\" >EdiGENE raises USD 15M to progress its pipeline<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-60\/#Antengene_announces_its_expansion_in_the_US\" >Antengene announces its expansion in the U.S.<\/a><\/li><\/ul><\/nav><\/div>\n\n<h4 class=\"wp-block-heading\" id=\"h-inozyme-pharma-raises-usd-67-million-in-series-a2-financing\"><span class=\"ez-toc-section\" id=\"Inozyme_Pharma_Raises_USD_67_Million_in_Series_A2_Financing\"><\/span><strong>Inozyme Pharma Raises USD 67 Million in Series A2 Financing<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h4>\n\n\n\n<p class=\"has-very-light-gray-background-color has-background\"><strong>Inozyme Pharma<\/strong>&#8211; a Boston-based biotechnology company, solely focused on developing novel therapies to treat <strong>rare diseases<\/strong>, has raised <strong>USD 67 million<\/strong>. The company plans to use this funding to progress its lead asset<strong> INZ-701<\/strong>, into clinical trials. INZ-701 is an enzyme which will be used to compensate for the lack of plasma pyrophosphate, which is known to cause a rare mineralisation disorder of the circulatory system, <strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/bone-metastasis-market\">bones<\/a><\/strong>, and <strong>kidneys<\/strong>. <\/p>\n\n\n\n<h4 class=\"wp-block-heading\" id=\"h-shanghai-miracogen-partners-with-synaffix-to-accelerate-its-pipeline\"><span class=\"ez-toc-section\" id=\"Shanghai_Miracogen_partners_with_Synaffix_to_accelerate_its_pipeline\"><\/span><strong>Shanghai Miracogen partners with Synaffix to accelerate its pipeline <\/strong><span class=\"ez-toc-section-end\"><\/span><\/h4>\n\n\n\n<p class=\"has-very-light-gray-background-color has-background\"> <strong>Shanghai Miracogen<\/strong>-a leading China-based <strong>antibody-drug conjugate <\/strong>(<strong>ADC<\/strong>) developer, has partnered with <strong>Synaffix BV-<\/strong>a Dutch-based Biotech company. <strong>Synaffix <\/strong>plans to advance the development of its <strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/metastatic-hormone-refractory-prostate-cancer-market\">cancer <\/a><\/strong>treatment regime, in a high-priced deal worth USD 125 million. ADC is emerging <a href=\"https:\/\/www.delveinsight.com\/report-store\/cervical-cancer-market\"><strong>cancer<\/strong> <\/a>therapies that combine an antibody with a potent anti-cancer drug. In this research collaboration, Shanghai Miracogen will be undertaking the research, development, manufacturing and commercialisation of the ADC product whereas, Synaffix will manufacture components that are specifically related to its proprietary <strong>GlycoConnect <\/strong>and <strong>HydraSpace <\/strong>technologies.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\" id=\"h-edigene-raises-usd-15m-to-progress-its-pipeline\"><span class=\"ez-toc-section\" id=\"EdiGENE_raises_USD_15M_to_progress_its_pipeline\"><\/span><strong>EdiGENE raises USD 15M to progress its pipeline <\/strong><span class=\"ez-toc-section-end\"><\/span><\/h4>\n\n\n\n<p class=\"has-very-light-gray-background-color has-background\"><strong>EdiGENE-<\/strong>an emerging Japanese biotechnology company, developing new <strong>CRISPR <\/strong>has raised USD 15 Million. The company is capable of regulating the levels of gene expression without cutting the <strong>DNA <\/strong>or <strong>RNA<\/strong>. The funds will be used to develop therapeutics using its <strong>CRISPR<\/strong>&#8211;<strong>GNDM <\/strong>(<strong>Guide Nucleotide Directed Modulation<\/strong>) technology.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\" id=\"h-antengene-announces-its-expansion-in-the-u-s\"><span class=\"ez-toc-section\" id=\"Antengene_announces_its_expansion_in_the_US\"><\/span><g class=\"gr_ gr_6 gr-alert gr_spell gr_inline_cards gr_run_anim ContextualSpelling ins-del multiReplace\" id=\"6\" data-gr-id=\"6\"><strong>Antengene<\/strong><\/g><strong> announces its expansion in the U.S.<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h4>\n\n\n\n<p class=\"has-very-light-gray-background-color has-background\"><strong><g class=\"gr_ gr_4 gr-alert gr_spell gr_inline_cards gr_run_anim ContextualSpelling ins-del multiReplace\" id=\"4\" data-gr-id=\"4\">Antengene<\/g> Corporation<\/strong>, a U.S. based <g class=\"gr_ gr_14 gr-alert gr_spell gr_inline_cards gr_run_anim ContextualSpelling ins-del multiReplace\" id=\"14\" data-gr-id=\"14\">clinical stage<\/g> biopharmaceutical company, has announced it\u2019s the establishment of its U.S. subsidiary and a collaboration with the non-profit <strong>Baruch S. Blumberg Institute<\/strong>. The latter based in the Pennsylvania Biotechnology Center is where the Antengene US subsidiary is also located. <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Inozyme Pharma Raises USD 67 Million in Series A2 Financing Inozyme Pharma&#8211; a Boston-based biotechnology company, solely focused on developing novel therapies to treat rare diseases, has raised USD 67 million. The company plans to use this funding to progress its lead asset INZ-701, into clinical trials. INZ-701 is an enzyme which will be used [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":4738,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":1,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[60,3191,77,3190,3194,137,647,3204,3186,3205,3203,3189,3192,3193,3206,3187,3188],"industry":[17225],"therapeutic_areas":[17235,17228,17234],"class_list":["post-4733","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-adc","tag-antengene-corporation","tag-antibody-drug-conjugate","tag-baruch-s-blumberg-institute","tag-bones","tag-cancer","tag-crispr","tag-edigene","tag-glycoconnect","tag-gndm","tag-guide-nucleotide-directed-modulation","tag-hydraspace","tag-inozyme-pharma","tag-inz-701","tag-kidneys","tag-shanghai-miracogen","tag-synaffix","industry-pharmaceutical","therapeutic_areas-cell-and-gene-therapy","therapeutic_areas-oncology","therapeutic_areas-rare-diseases"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Inozyme Raises $67M; Shanghai Miracogen partners with Synaffix<\/title>\n<meta name=\"description\" content=\"Inozyme Pharma- a biotechnology company solely focused on developing novel therapies to treat rare diseases, has raised USD 67 million. The Boston based...\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-60\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Inozyme Raises $67M; Shanghai Miracogen partners with Synaffix\" \/>\n<meta property=\"og:description\" content=\"Inozyme Pharma- a biotechnology company solely focused on developing novel therapies to treat rare diseases, has raised USD 67 million. The Boston based...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-60\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2019-04-11T11:03:31+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-06-14T06:19:02+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/04\/09021810\/My-Post-1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"647\" \/>\n\t<meta property=\"og:image:height\" content=\"345\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Inozyme Raises $67M; Shanghai Miracogen partners with Synaffix","description":"Inozyme Pharma- a biotechnology company solely focused on developing novel therapies to treat rare diseases, has raised USD 67 million. The Boston based...","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-60","og_locale":"en_US","og_type":"article","og_title":"Inozyme Raises $67M; Shanghai Miracogen partners with Synaffix","og_description":"Inozyme Pharma- a biotechnology company solely focused on developing novel therapies to treat rare diseases, has raised USD 67 million. The Boston based...","og_url":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-60","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2019-04-11T11:03:31+00:00","article_modified_time":"2023-06-14T06:19:02+00:00","og_image":[{"width":647,"height":345,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/04\/09021810\/My-Post-1.jpg","type":"image\/jpeg"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-60","url":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-60","name":"Inozyme Raises $67M; Shanghai Miracogen partners with Synaffix","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-60#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-60#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/04\/09021810\/My-Post-1.jpg","datePublished":"2019-04-11T11:03:31+00:00","dateModified":"2023-06-14T06:19:02+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"Inozyme Pharma- a biotechnology company solely focused on developing novel therapies to treat rare diseases, has raised USD 67 million. The Boston based...","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-60"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-60#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/04\/09021810\/My-Post-1.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/04\/09021810\/My-Post-1.jpg","width":647,"height":345,"caption":"The Business Cocktail"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/04\/09021810\/My-Post-1-300x160.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">ADC<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Antengene Corporation<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Antibody-Drug Conjugate<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Baruch S. Blumberg Institute<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">bones<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Cancer<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">CRISPR<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">EdiGENE<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">GlycoConnect<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">GNDM<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Guide Nucleotide Directed Modulation<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">HydraSpace<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Inozyme Pharma<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">INZ-701<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">kidneys<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Shanghai Miracogen<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Synaffix<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">ADC<\/span>","<span class=\"advgb-post-tax-term\">Antengene Corporation<\/span>","<span class=\"advgb-post-tax-term\">Antibody-Drug Conjugate<\/span>","<span class=\"advgb-post-tax-term\">Baruch S. Blumberg Institute<\/span>","<span class=\"advgb-post-tax-term\">bones<\/span>","<span class=\"advgb-post-tax-term\">Cancer<\/span>","<span class=\"advgb-post-tax-term\">CRISPR<\/span>","<span class=\"advgb-post-tax-term\">EdiGENE<\/span>","<span class=\"advgb-post-tax-term\">GlycoConnect<\/span>","<span class=\"advgb-post-tax-term\">GNDM<\/span>","<span class=\"advgb-post-tax-term\">Guide Nucleotide Directed Modulation<\/span>","<span class=\"advgb-post-tax-term\">HydraSpace<\/span>","<span class=\"advgb-post-tax-term\">Inozyme Pharma<\/span>","<span class=\"advgb-post-tax-term\">INZ-701<\/span>","<span class=\"advgb-post-tax-term\">kidneys<\/span>","<span class=\"advgb-post-tax-term\">Shanghai Miracogen<\/span>","<span class=\"advgb-post-tax-term\">Synaffix<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 7 years ago","modified":"Updated 3 years ago"},"absolute_dates":{"created":"Posted on Apr 11, 2019","modified":"Updated on Jun 14, 2023"},"absolute_dates_time":{"created":"Posted on Apr 11, 2019 4:33 pm","modified":"Updated on Jun 14, 2023 11:49 am"},"featured_img_caption":"","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/4733","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=4733"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/4733\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/4738"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=4733"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=4733"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=4733"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=4733"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=4733"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}